A different kind of fundraiser, fun & active!
We are spinning for a great cause. Raising money and awareness for
Usher Syndrome Type 1F. We MUST find a cure, so come and spin.
Expert, beginner, wannabe spinner, doesn’t matter your level, we are spinning for Zachary Root and others with Usher Syndrome. 100% of proceeds goes directly for research through the Usher 1f Collaborative, a 501(c)3 organization.
DON’T MISS YOUR CHANCE TO HELP!
What is Usher Syndrome
Usher Syndrome is the leading cause of deaf-blindness in the world. The major symptoms of Usher syndrome are hearing loss, poor balance and an eye disorder called retinitis pigmentosa, or RP. RP first causes night-blindness, then loss of peripheral vision, and eventually total blindness through the progressive degeneration of the retina. Type 1 is the most severe, with deafness and poor balance from birth and symptoms of retinitis pigmentosa beginning in the first decade of life. Thankfully, through the use of cochlear implants, children born today with Usher Syndrome 1F are given access to sound at an early age and are able to learn how to listen and speak. There is currently NO CURE or treatment to save their vision.
Usher syndrome is inherited, which means it is passed from parents to their children through genes. As many as 5% of Ashkenazi Jews carry the genetic mutation for Usher Syndrome and about 2.5% carry the Usher 1F mutation. When both parents carry the mutation, there is a 25% chance they will have a child with Usher syndrome.
Sustainable Pathway to a Cure
Investing in research will enable Usher 1F Collaborative to continue to fund the medical researchers who are currently working to cure Usher 1F and to expand our work and engage additional retinal researchers.
Edwin Stone, M.D., Ph.D., at the University of Iowa Wynn Institute for Vision Research, is developing gene replacement therapy, a technique used successfully for other types of retinitis pigmentosa, to replace the mutated gene in the eye, as well as stem cell therapy using patients’ own skin cells, to halt further progression of vision loss and restore lost vision.
Monte Westerfield, Ph.D., at the University Of Oregon Institute Of Neuroscience, has developed a zebrafish model of the Usher 1F mutation and is about to begin testing of drugs that hold the potential to halt or slow the progression of vision loss.
Zubair Ahmed, Ph.D., at the University of Maryland, has developed a mouse model of the Usher 1F mutation which he will be using, in collaboration with Monte Westerfield, to test promising drugs. In addition, he is working with Livia Carvalho, Ph.D., University of Western Australia, to develop another approach to gene replacement therapy.
To date our organization has raised almost $1 million and granted $700,000 to these four top researchers.